SCPH deal: insiders cashed out for $5.35 and contingent $1 CVR
Rhea-AI Filing Summary
scPharmaceuticals Inc. completed a merger with MannKind Corporation, effective 10/07/2025, after a Purchaser tender offer that paid $5.35 per share plus one non-tradable contingent value right (CVR) per share representing a potential additional $1.00 payment if a specified milestone is achieved. The reporting person, John H. Tucker (President and CEO and Director), reported disposition of 318,502 shares and a deemed sale/transfer of 122,345 shares on the same date, leaving 0 common shares beneficially owned following the transactions. Time-based RSU awards accelerated, converted into cash at $5.35 per share plus one CVR per share, and in-the-money stock options with exercise prices below $5.35 were cancelled and converted into cash payments equal to the spread plus one CVR per option share.
Positive
- Cash consideration of $5.35 per share provided immediate liquidity to shareholders
- RSU acceleration and cash conversion guaranteed recipients received value without future vesting uncertainty
- Options converted for cash eliminated potential future dilution from exercised shares
Negative
- Reporting person disposed of 318,502 shares, resulting in 0 common shares beneficially owned post-transaction
- CVR is contingent and only provides an additional $1.00 per share if a milestone is met, so full consideration is not certain
- Tax withholding applied to cash payouts may reduce net proceeds to award holders
Insights
Executive holdings were fully cashed out by the merger, simplifying ownership structure.
The merger resulted in an immediate cash settlement of outstanding equity awards and acceleration of RSUs, replacing vested equity with cash and one CVR per share. This removes insider common-stock exposure and centralizes ownership under the parent company.
Key dependencies include the CVR milestone outcome and any tax withholdings; monitor the realization of the $1.00 CVR payment and any disclosures on tax withholding timing within the next 12 months.
In-the-money options were cashed out at the merger spread, terminating option overhang.
Options with exercise prices below $5.35 were cancelled and converted into cash equal to the per-share spread times shares, and RSUs were converted into immediate cash plus CVRs. The transactions remove future dilution from these awards and crystallize executive compensation value.
Watch for the aggregate cash payout figure in post-merger statements and any tax reporting for option and RSU settlements during the current tax year.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Stock Option (Right to Buy) | 300,000 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 84,500 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 249,000 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 496,674 | $0.00 | -- |
| U | Common Stock | 122,345 | $0.00 | -- |
| Disposition | Common Stock | 318,502 | $0.00 | -- |
Footnotes (1)
- In connection with the terms of an Agreement and Plan of Merger, dated as of August 24, 2025 (as amended, the "Merger Agreement"), by and among the Issuer, MannKind Corporation ("Parent") and Seacoast Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. Tendering stockholders received per share consideration of $5.35 in cash per share, subject to any applicable withholding taxes and without interest thereon, plus one non-tradable contingent value right ("CVR") per share, representing the right to receive one contingent payment of $1.00, in cash, (Continued from footnote 1) subject to any applicable withholding taxes and without interest thereon, upon achievement of the specified milestone. After completion of the tender offer, Purchaser merged with and into the Issuer (the "Merger"), effective as of October 7, 2025 (the "Effective Time"), with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each time-based restricted stock unit award with respect to shares that is, at the time of determination, subject to vesting or forfeiture conditions ("RSU Award") that is outstanding as of immediately prior thereto, shall (a) accelerate and become fully vested, and (b) by virtue of the Merger automatically (except as otherwise provided in the Merger Agreement) and without any action on the part of the Issuer, Parent or the holder thereof, be canceled and terminated and converted into the right to receive (i) an amount in cash equal to the product of the number of shares underlying such RSU Award immediately prior to the Effective Time multiplied by $5.35, subject to any applicable withholding taxes and without interest thereon plus (ii) one CVR with respect to each share subject to such RSU Award immediately prior to the Effective Time. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares (a "Company Option") that is outstanding and unexercised as of immediately prior to the Effective Time and that that has an exercise price per share that is less than $5.35, whether or not then vested or exercisable, was cancelled and converted into the right to receive (i) an amount in cash, without interest and subject to any applicable withholding taxes, equal to (A) the total number of shares subject to such Company Option immediately prior to such cancellation multiplied by (B) the excess, if any, of (x) $5.35 over (y) the exercise price payable per share underlying such Company Option and (ii) one CVR in respect of each Share subject to such Company Option.
